IFNG and cancer: Thus, for cancer immunotherapy, strategies for increasing intra-tumoral IFNγ expression could improve antigen presentation, not only in tumors where MHC I and/or tapasin downregulation results from regulatory alterations that can be reversed by IFNγ treatment but, importantly, also in tumors that have permanently lost tapasin expression.